Eligibility Criteria:
Patients with locally advanced breast cancer
Female patients aged ≥ 18 years at the time of screening
Participants will receive all medications and investigations as a part of the trial.
For more information contact:
+91 81080 06207 (Prathmesh Mane)
Email: prathmesh.mane@sunactcancer.com
You may qualify if you:
Are a female patient aged 18 years or older at the time of screening
Have HER2-negative breast cancer
Have a BRCA1, BRCA2, or PALB2 gene mutation and are Hormone Receptor-Positive
A Phase III Randomized Controlled Trial in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Study Overview:
Design: Randomized, open-label, non-inferiority cum superiority (1:1)
Population: 438 patients with locally advanced, resectable esophageal squamous carcinoma
Arms:
Arm A: Neoadjuvant chemoradiation (CROSS protocol – Paclitaxel, Carboplatin, RT)
Arm B: Neoadjuvant triple-drug chemotherapy (Docetaxel/Paclitaxel, Cisplatin/Carboplatin, 5 FU/Capecitabine) + Low-dose Nivolumab (40 mg)
Eligibility Criteria:
Histologically confirmed esophageal squamous carcinoma (locally advanced, resectable)
ECOG 0–2
Adequate organ function
Principal Investigator
+91 70216 20792 (Dr. Minit Shah)
Email: minitjshah@gmail.com
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
Share your details below, and we’ll reach out to you without delay.
Disclaimer : We will be using this information for calling purposes only.
